Zhejiang Jolly PharmaceuticalLTD Third Quarter 2024 Earnings: EPS: CN¥0.18 (vs CN¥0.13 in 3Q 2023)
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥616.6m (up 36% from 3Q 2023).
- Net income: CN¥125.4m (up 41% from 3Q 2023).
- Profit margin: 20% (in line with 3Q 2023).
- EPS: CN¥0.18 (up from CN¥0.13 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Zhejiang Jolly PharmaceuticalLTD Earnings Insights
Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China.
Performance of the Chinese Pharmaceuticals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Zhejiang Jolly PharmaceuticalLTD, and understanding it should be part of your investment process.
Valuation is complex, but we're here to simplify it.
Discover if Zhejiang Jolly PharmaceuticalLTD might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300181
Zhejiang Jolly PharmaceuticalLTD
Engages in the research, production, and marketing of Chinese medicinal products in the People’s Republic of China and internationally.
Flawless balance sheet with high growth potential and pays a dividend.